查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1768522

伽玛刀全球市场

Gamma Knife
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球伽玛刀市场规模将达到 4.039 亿美元

全球伽玛刀市场规模预计在2024年为3.108亿美元，到2030年将达到4.039亿美元，在2024-2030年的分析期间内，复合年增长率为4.5%。作为本报告分析的细分市场之一，恶性肿瘤市场预计将以4.7%的复合年增长率成长，到分析期结束时达到2.211亿美元。良性肿瘤市场的复合年增长率预计在分析期间为4.4%。

美国市场规模估计为 8,220 万美元，中国市场预计复合年增长率为 6.9%

美国伽玛刀市场规模预计2024年达到8,220万美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到8,730万美元，在2024-2030年的分析期内，复合年增长率为6.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为2.9%和3.7%。在欧洲，预计德国市场的复合年增长率为3.4%。

全球伽玛刀市场－定义、关键趋势与驱动因素摘要

什么是伽玛刀？为什么它在现代神经外科中如此重要？

伽玛刀是一种立体定位放射放射线手术(SRS) 手术，用于治疗脑肿瘤、血管畸形和其他神经系统疾病，且无需侵入性手术。但为什么伽玛刀被认为是神经外科领域的突破性治疗方法呢？与传统手术不同，伽玛刀使用聚焦的伽玛射线束精准瞄准异常脑组织，并在不损害周围健康组织的情况下释放高剂量辐射。这种非侵入性手术以其精准、有效和快速恢復而闻名，使其成为脑转移瘤、动静脉畸形 (AVM)、三叉神经痛以及某些良性和恶性脑肿瘤患者的首选治疗方案。由于伽玛刀无需物理切口，它可以最大限度地降低传统脑外科手术的风险，例如感染、出血和较长的恢復时间。随着对微创治疗的需求日益增长，伽玛刀技术因其能够精准治疗复杂的脑部疾病且副作用极小，在现代神经外科中的重要性日益凸显。

科技进步如何影响伽玛刀市场？

技术创新在伽玛刀系统的进步中发挥了关键作用。但这些进步是如何提高治疗的有效性和安全性的呢？一项重大进展是将核磁共振和电脑断层扫描等先进成像技术与伽玛刀系统相结合，从而改善了治疗计划并提高了治疗精度。这些影像技术可以更精确地定位脑部病变，使放射线能够准确地输送到所需的位置，最大限度地减少对健康组织的损伤。此外，即时影像处理和3D治疗计划软体的引入提高了剂量传输的准确性，从而可以更有针对性地治疗脑转移瘤和动静脉畸形（AVM）等疾病。

另一项重要的创新是伽玛刀技术本身的演进。最新版本的伽玛刀系统，例如Icon伽玛刀，配备了先进的运动追踪和固定係统，可实现无框架治疗，减轻患者不适，并扩大了治疗范围。此外，新系统采用分次照射，这意味着可以根据需要分次进行放射治疗，从而为治疗更大或更复杂的病灶提供了更大的灵活性。

这些技术进步使得伽玛刀治疗更安全、更舒适、更有效，帮助医疗保健提供者扩大放射线手术在更广泛的神经系统疾病的应用。

监管和医疗保健趋势如何影响伽玛刀市场？

法律规范和医疗保健趋势在塑造伽玛刀市场方面发挥什么作用？美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构在确保伽玛刀技术的安全性和有效性方面发挥关键作用。严格的监管标准指导着伽玛刀系统等医疗设备的核准和使用，确保这些治疗符合安全要求并提供一致的高品质护理。此外，医疗保健提供者必须遵守辐射安全标准，随着立体定位放射线手术在全球的推广，这一点变得越来越重要。

日益增长的价值导向型医疗保健趋势也影响着伽玛刀技术的普及。随着医疗保健体系转向以结果为导向的模式，像伽玛刀这样精准度高、副作用少、恢復时间短的治疗方法，对患者和医疗服务提供者都越来越有吸引力。与需要较长住院时间和復原时间的传统开放性手术相比，非侵入性手术更具成本效益，促使更多医院和诊所投资伽玛刀技术。此外，对微创手术日益增长的需求正在推动全球立体定位放射线手术中心的扩张，尤其是在亚太和拉丁美洲等地区。

此外，全球癌症发生率（尤其是脑转移瘤）的上升预计将推动对伽玛刀等先进放射外科工具的需求。这些监管和医疗保健趋势正在塑造市场，确保伽玛刀仍然是治疗复杂脑部疾病的安全、有效且经济可行的选择。

推动伽玛刀市场成长的关键因素有哪些？

伽玛刀市场的成长受到几个关键因素的推动，包括脑部疾病盛行率的上升、放射外科技术的进步以及对微创治疗方案的需求不断增长。主要驱动因素之一是脑肿瘤、血管畸形和神经病变的盛行率上升，这推动了对精确有效治疗方法的需求。伽玛刀放射放射线手术因其能够以最小的风险治疗这些疾病而广受认可，使其成为不适合传统手术的患者的首选。影像和放射技术的进步提高了伽玛刀治疗的准确性和安全性，这也是一个主要驱动因素。这些技术创新使医疗保健提供者能够治疗更复杂的病例，改善患者的治疗效果，并减少副作用。此外，人口老化也促进了伽玛刀市场的成长，因为老年患者通常患脑部疾病的风险更高，并且更倾向于寻求非侵入性治疗。

随着患者和医疗保健提供者寻求恢復更快、併发症更少的治疗方法，对门诊治疗的需求也在上升。伽玛刀治疗通常不需要住院过夜，这使其成为门诊病人的理想选择。全球伽玛刀中心的数量不断增加，尤其是在新兴市场，随着越来越多的医疗保健提供者投资这项最尖端科技，这进一步推动了市场扩张。对非侵入性治疗的需求不断增长、技术进步以及神经系统疾病负担的增加，推动全球伽玛刀市场强劲成长，使其成为未来神经外科的关键工具。

部分

适应症（恶性肿瘤、良性肿瘤、血管性疾病、功能性疾病、眼科疾病）

受访公司范例

  • Accuray, Inc.
  • Brainlab AG
  • Elekta AB
  • Elsan SAS
  • IBA Dosimetry GmbH
  • Mevion Medical Systems, Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Sun Nuclear Corporation
  • Varian Medical Systems, Inc.
  • Zap Surgical Systems Inc.

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP21871

Global Gamma Knife Market to Reach US$403.9 Million by 2030

The global market for Gamma Knife estimated at US$310.8 Million in the year 2024, is expected to reach US$403.9 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Malignant Tumors, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Benign Tumors segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.2 Million While China is Forecast to Grow at 6.9% CAGR

The Gamma Knife market in the U.S. is estimated at US$82.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Gamma Knife Market - Definition, Key Trends & Drivers Summarized

What Is Gamma Knife and Why Is It Important in Modern Neurosurgery?

Gamma Knife is a form of stereotactic radiosurgery (SRS) used to treat brain tumors, vascular malformations, and other neurological conditions without invasive surgery. But why is Gamma Knife considered a breakthrough in neurosurgery? Unlike traditional surgery, Gamma Knife uses focused beams of gamma radiation to precisely target abnormal tissue in the brain, delivering high doses of radiation without harming surrounding healthy tissue. This non-invasive procedure is known for its accuracy, effectiveness, and reduced recovery time, making it a preferred option for patients with conditions like brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, and certain types of benign and malignant brain tumors. Since Gamma Knife does not require physical incisions, the risks associated with traditional brain surgery-such as infection, bleeding, and extended recovery-are minimized. As demand for less invasive treatments grows, Gamma Knife technology has become increasingly important in modern neurosurgery for its ability to treat complex brain conditions with precision and minimal side effects.

How Are Technological Advancements Shaping the Gamma Knife Market?

Technological innovations are playing a key role in advancing Gamma Knife systems. But how are these advancements improving the effectiveness and safety of the procedure? One major development is the integration of advanced imaging technologies, such as MRI and CT scans, with Gamma Knife systems to enhance treatment planning and accuracy. These imaging techniques allow for more precise localization of brain lesions, ensuring that radiation is delivered exactly where it is needed, minimizing damage to healthy tissue. The incorporation of real-time imaging and 3D treatment planning software has also improved the precision of dose delivery, enabling more targeted treatments for conditions like brain metastases and AVMs.

Another key innovation is the evolution of the Gamma Knife technology itself. The latest versions of Gamma Knife systems, such as the Gamma Knife Icon, feature advanced motion tracking and immobilization systems, allowing for frameless treatments. This reduces patient discomfort and expands the range of treatable conditions. Moreover, new systems offer the ability to deliver fractionated treatments, meaning that radiation can be delivered over multiple sessions if needed, providing more flexibility for treating larger or more complex lesions.

These technological advancements are making Gamma Knife treatments safer, more comfortable, and more effective, helping healthcare providers expand the use of radiosurgery for a broader range of neurological conditions.

How Are Regulations and Healthcare Trends Impacting the Gamma Knife Market?

What role do regulatory frameworks and healthcare trends play in shaping the Gamma Knife market? Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety and efficacy of Gamma Knife technology. Strict regulatory standards guide the approval and use of medical devices like Gamma Knife systems, ensuring that these treatments meet safety requirements and deliver consistent, high-quality care. Additionally, healthcare providers must comply with radiation safety standards, which are becoming increasingly important as the use of stereotactic radiosurgery expands globally.

The growing trend toward value-based healthcare is also influencing the adoption of Gamma Knife technology. As healthcare systems shift toward outcomes-based models, treatments that offer high precision, reduced side effects, and shorter recovery times-such as Gamma Knife-are becoming more attractive to both patients and providers. The cost-effectiveness of non-invasive procedures, compared to traditional open surgery with longer hospitalization and rehabilitation periods, is encouraging more hospitals and clinics to invest in Gamma Knife technology. Moreover, the rising demand for minimally invasive treatments is driving the expansion of stereotactic radiosurgery centers globally, with particular growth in regions such as Asia-Pacific and Latin America.

Furthermore, as the global burden of cancer continues to rise, particularly with the increasing incidence of brain metastases, the need for advanced radiosurgical tools like Gamma Knife is expected to grow. These regulatory and healthcare trends are shaping the market by ensuring that Gamma Knife remains a safe, effective, and financially viable option for treating complex brain conditions.

What Are the Key Drivers Behind the Growth of the Gamma Knife Market?

The growth in the Gamma Knife market is driven by several key factors, including the increasing incidence of brain disorders, advancements in radiosurgical technology, and the growing demand for minimally invasive treatment options. One of the primary drivers is the rising prevalence of brain tumors, vascular malformations, and neurological disorders, which has increased the need for precise and effective treatment modalities. Gamma Knife radiosurgery is widely recognized for its ability to treat these conditions with minimal risk, making it a preferred choice for patients who are not candidates for traditional surgery. Another significant driver is the advancement in imaging and radiation technologies, which have enhanced the accuracy and safety of Gamma Knife treatments. These innovations allow healthcare providers to treat more complex cases, improve patient outcomes, and reduce side effects. Additionally, the aging global population is contributing to the growth of the Gamma Knife market, as elderly patients are often at higher risk for brain conditions and are more likely to seek non-invasive treatments.

The demand for outpatient procedures is also rising, as patients and healthcare providers seek treatments that offer faster recovery times and fewer complications. Gamma Knife treatments typically require no overnight hospital stay, making them an appealing option in outpatient settings. The growing availability of Gamma Knife centers worldwide, particularly in emerging markets, is further driving the expansion of the market as more healthcare providers invest in this cutting-edge technology. Together, these factors-rising demand for non-invasive treatments, technological advancements, and the increasing burden of neurological diseases-are driving robust growth in the global Gamma Knife market, positioning it as a key tool in the future of neurosurgery.

SCOPE OF STUDY:

The report analyzes the Gamma Knife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Accuray, Inc.
  • Brainlab AG
  • Elekta AB
  • Elsan SAS
  • IBA Dosimetry GmbH
  • Mevion Medical Systems, Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Sun Nuclear Corporation
  • Varian Medical Systems, Inc.
  • Zap Surgical Systems Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Gamma Knife - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Brain Tumors and Neurological Disorders Drives Demand for Gamma Knife Radiosurgery
    • Technological Advancements in Gamma Knife Systems Propel Growth in Precision Treatment for Complex Brain Conditions
    • Increasing Adoption of Non-Invasive Treatment Solutions Expands Market for Gamma Knife as a Preferred Alternative to Traditional Surgery
    • Growing Focus on Minimally Invasive Neurosurgery Fuels Demand for Gamma Knife in the Treatment of Brain Metastases and Arteriovenous Malformations (AVMs)
    • Rising Demand for Outpatient Treatment Options Strengthens the Business Case for Gamma Knife Radiosurgery Due to Shorter Recovery Times
    • Increasing Use of Gamma Knife for Treating Functional Disorders, Such as Trigeminal Neuralgia, Expands Clinical Applications
    • Technological Innovations in Imaging and Targeting Techniques Propel Growth in Real-Time Monitoring and Enhanced Treatment Accuracy
    • Rising Global Awareness of Stereotactic Radiosurgery (SRS) Strengthens Market Demand for Gamma Knife in Neurological and Oncological Treatments
    • Growing Emphasis on Reducing Side Effects and Enhancing Patient Outcomes Fuels Adoption of Gamma Knife for High-Precision Radiosurgery
    • Increasing Focus on Elderly Patients and Their Unique Treatment Needs Expands Market for Gamma Knife as a Safe and Effective Option
    • Technological Advancements in Motion Tracking and Immobilization Systems Support Growth in Frameless Gamma Knife Treatments
    • Rising Adoption of Gamma Knife in Pediatric Neurosurgery Expands Market for Non-Invasive Treatment of Pediatric Brain Disorders
    • Growing Focus on Value-Based Healthcare Drives Adoption of Gamma Knife as a Cost-Effective Alternative to Open Surgery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Malignant Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Benign Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Vascular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Functional Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Ocular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Gamma Knife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Japan 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: China 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: France 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Germany 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Italy 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: UK 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Spain 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Russia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Australia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: India 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: South Korea 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Argentina 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Brazil 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Mexico 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Iran 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Israel 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UAE 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Africa 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION